Guohui Cui

机构：Union Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-0520-4526

发表论文 107 篇 · 总被引 1433 次 · h-index 19

代表论文

• Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials (2023 · Blood · 被引 14)
• Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis (2023 · Clinical and Experimental Medicine · 被引 10)
• Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial (2024 · The Lancet Regional Health - Western Pacific · 被引 7)
• Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2 (2025 · Frontiers in Immunology · 被引 5)
• Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results (2023 · Blood · 被引 4)
• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)